The Secret of Longevity

Rapamycin has been researched by many doctors and academicians and articles have been published about its benefits. As we know, in addition to supporting a long and healthy life, it is also anti-cancer, making it a very valuable supplement. Now let’s look at what a few people have to say about Rapamycin.

Dr. David Sinclair (Harvard University Professor, Aging Researcher)

Dr. David Sinclair is a well-known researcher in the field of aging and has extensively studied compounds that might extend lifespan. He has mentioned rapamycin as one of the key substances in aging research, alongside other compounds like NAD+ precursors and resveratrol. Sinclair’s work revolves around understanding the biology of aging, and he has highlighted rapamycin’s role in promoting autophagy (cellular cleanup), mTOR inhibition, and potential longevity benefits.

What Dr. Sinclair said about rapamycin:

• In his 2019 book “Lifespan: Why We Age – and Why We Don’t Have To”, Sinclair discusses how mTOR (the target of rapamycin) is a key protein involved in regulating cell growth, metabolism, and aging.
• Sinclair mentions that inhibiting mTOR, particularly through drugs like rapamycin, can increase lifespan in various organisms, from yeast to mice.
• He also notes that while rapamycin has shown promising results in animal models, it remains a subject of ongoing research, especially regarding its potential risks and benefits for humans. Sinclair is cautious about recommending rapamycin for humans without further studies but recognizes its importance in understanding aging.

“Rapamycin may very well be the most potent longevity drug discovered to date… It has shown a remarkable ability to extend life in various animals. If it works similarly in humans, it could have a profound impact on aging and age-related diseases.”
— Dr. David Sinclair, Lifespan (2019)

Dr. Brian Kennedy (Biogerontologist, Director of the Centre for Healthy Ageing)

Dr. Brian Kennedy is another prominent researcher focused on aging. He has studied rapamycin extensively in the context of lifespan extension and age-related diseases. As an advocate for mTOR inhibition as a potential anti-aging strategy, Dr. Kennedy has been involved in studies showing that rapamycin can extend lifespan in mice.

What Dr. Kennedy said about rapamycin:

• Dr. Kennedy has stated that while the potential for rapamycin to extend life in humans is exciting, we still need more evidence. He has highlighted its impact on autophagy and its ability to prevent cellular damage.
• He also underscores that rapamycin’s effects could help combat age-related diseases such as Alzheimer’s, cardiovascular diseases, and cancer.
• Kennedy is careful to note that while rapamycin is one of the few drugs that has been shown to extend lifespan in animals, its human application needs further investigation.

“Rapamycin and other mTOR inhibitors hold great promise as tools for extending lifespan and promoting healthspan. However, we still have a lot to learn about their long-term safety and effectiveness in humans.”
— Dr. Brian Kennedy, Interview, 2016

Dr. James L. Kirkland (Mayo Clinic, Aging and Longevity Researcher)

Dr. James L. Kirkland is a prominent researcher in the field of aging and regenerative medicine. He has conducted research on senescence (the aging of cells) and the potential for rapamycin and other compounds to target senescent cells. Rapamycin is often discussed in the context of its ability to delay aging and counteract diseases of aging.

What Dr. Kirkland said about rapamycin:

• Dr. Kirkland has pointed to rapamycin as one of the most promising anti-aging therapies. He has specifically noted that mTOR inhibition via rapamycin can reverse signs of aging in various organs and extend health span in older organisms.
• He acknowledges that there is still much research to be done, particularly regarding side effects and long-term safety in humans, but he believes rapamycin could play an important role in aging and regenerative medicine.

“Rapamycin has shown great promise in slowing aging in mice and could eventually be used to treat age-related diseases in humans. It targets the mTOR pathway, which is central to aging and longevity.”
— Dr. James Kirkland, 2018

Dr. David Gems (University College London, Biogerontologist)

Dr. David Gems is a well-known biogerontologist who has studied the genetic pathways involved in aging, including the role of mTOR and the effects of rapamycin. His research often focuses on how drugs like rapamycin can extend healthy lifespan and delay age-related diseases.

What Dr. Gems said about rapamycin:

• Dr. Gems has expressed excitement about rapamycin’s potential to help extend lifespan and treat age-related diseases. However, he has pointed out that practical use in humans would require a better understanding of the drug’s long-term effects and safety.
• He has been cautious in recommending rapamycin for humans, despite its positive effects in laboratory animals, but sees its potential as part of a broader approach to aging research.

“Rapamycin holds real promise as a treatment to delay aging and age-related diseases. However, much more research is needed to fully understand its potential and risks in humans.”
— Dr. David Gems, 2016

Dr. Nir Barzilai (Albert Einstein College of Medicine, Aging Researcher)

Dr. Nir Barzilai is a leader in aging research and is involved in studies aimed at extending healthy lifespan. He has also mentioned rapamycin in the context of its potential to delay the onset of diseases related to aging.

What Dr. Barzilai said about rapamycin:

• Dr. Barzilai has highlighted that rapamycin’s effects on autophagy and mTOR inhibition are promising for promoting healthy aging and potentially increasing lifespan.
• He has also pointed out that rapamycin is being studied in clinical trials, and he’s optimistic about its potential, though he stresses that careful testing in humans is essential before broad use.

“Rapamycin is one of the most promising compounds in aging research. It is showing impressive effects in preclinical models, but we need more research to confirm its effects in humans and determine its safety for long-term use.”
— Dr. Nir Barzilai, 2017